Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning. // European Urology Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2588931126002567?dgcid=rss_sd_all
Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning. European Urology Oncology. https://www.sciencedirect.com/science/article/pii/S2588931126002567?dgcid=rss_sd_all
“Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning.” European Urology Oncology.
@article{article93808,
title = {Adjuvant Pembrolizumab in Clear Cell Renal Cell Carcinoma: Eligibility Is Only the Beginning},
journal = {European Urology Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2588931126002567?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...